PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR ® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and BRISBANE, Australia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Anteris announced today it has received U.S. Food and Drug Administration (FDA) approval to initiate PARADIGM , its global Investigational Device Exemption (IDE) clinical trial... Read More

MINNEAPOLIS and BRISBANE, Australia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced one-year clinical outcomes for the DurAVR ® Transcatheter Heart Valve (THV) in symptomatic severe aortic... Read More

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the first patients have been enrolled and successfully treated in the DurAVR ®... Read More

MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the DurAVR ® Transcatheter Heart Valve (THV) will be presented... Read More

MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR ®... Read More

MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that after convening its Special Meeting of Stockholders (the “Special Meeting”) virtually on... Read More

MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that its Special Meeting of Stockholders (the “Special Meeting”), which was originally scheduled to... Read More

MINNEAPOLIS and BRISBANE, Australia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that its Special Meeting of Stockholders (the “Special Meeting”), which was originally scheduled to... Read More

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update. Second Quarter... Read More

New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today... Read More

MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. First Quarter... Read More

MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris ® or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR ®... Read More

MINNEAPOLIS and BRISBANE, Australia, March 21, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris ® or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced one-year results for patients treated with its proprietary, balloon expandable, DurAVR ®... Read More

EAGAN, Minn. and BRISBANE, Australia, March 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2024, and provided a corporate update. 2024... Read More

MINNEAPOLIS and BRISBANE, Australia, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Anteris ® Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a structural heart company developing DurAVR ® THV, a first-in-class, biomimetic, balloon expandable heart valve, is pleased to advise that Chief Executive Officer, Wayne Paterson will be presenting at both the 45 th Annual TD Cowen Healthcare Conference, and the... Read More

BRISBANE, Australia & EAGAN, Minn. / Dec 16, 2024 / Business Wire / Anteris Technologies Global Corp. (“ATGC” or “Anteris”) is pleased to announce the closing of its initial public offering of 14,800,000 shares of its common stock (the “Common Stock”) in the U.S. at a price of $6.00 per share (the “Offering”). An additional 2,220,000 shares of Common Stock are issuable pursuant to the underwriters’ option to purchase... Read More